Living-donor liver transplantation (LDLT) has been refined and accepted as a valuable treatment for patients with end-stage liver disease in order to overcome the shortage of organs and mortality on the waiting list. The aim of this study was to report our experience in LDLT. We retrospectively studied 50 living donor liver transplantations from January 1997 to March 2008 in organ transplant center of Namazi Hospital, Shiraz, Iran. We reviewed demographic data, family history, operation duration, hospital stay duration and post-operation complications in donors and recipients. A retrospective analysis of chemical and biochemical data of recipients was also performed. A total of 50 patients (30male, 20 female, 7.21 ± 5.35 y/o) underwent LDLT (10 right lobe, 38 left lobe and 2 left lateral segment). 47 received liver graft from parents, 2 from their brothers and one from uncle. The most common indications for LDLT were end-stage liver disease due to Wilson disease (16%), cryptogenic cirrhosis (16%), biliary atresia (12%) and autoimmune hepatitis (12%). The mean follow-up was 16.91 ± 23.74 months. There were 13 (26%) recipients mortality(5 due to vascular complications, 3 due to sepsis after bowel perforation, 2 from liver dysfunction, 2 from chronic rejection due to non-compliance, and 1 from diffuse aspergillosis) and morbidity rate was 50% (including 19 re-exploration during hospital course and 5 biliary complications). In conclusion, The study demonstrates that LDLT can play an important role in decreasing the number of patients in waiting list for liver transplantation especially in pediatric group. However, because of relatively high mortality and morbidity, we must use every effort to maximize our treatment outcome.